Answers are grounded in this paper and cite their sources.
Pediatric brain tumors are the leading cause of disease-related death in children, yet effective treatment remains a major clinical challenge. These aggressive tumors have limited therapeutic options capable of crossing the blood-brain barrier (BBB) and frequently recur due to genetic or epigenetic alterations and treatment resistance. Gene therapy offers a promising strategy to address these limitations by modifying gene expression, correcting mutations, or introducing functional genes. Nanoparticle (NP) delivery systems facilitate this approach by protecting genetic cargo and enabling BBB penetration and tumor-specific uptake. This review summarizes current genetic engineering strategies and NP-based delivery systems for pediatric brain tumors, including their design principles and delivery mechanisms, highlights key therapeutic approaches under preclinical and clinical investigations, and discusses the major challenges and future directions in NP-mediated gene therapy for pediatric neuro-oncology. By critically evaluating these developments, we aim to underscore the transformative potential of NP-mediated gene therapies in reshaping treatment paradigms and improving outcomes and quality of life for children.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: